Discovery of Ruthenium(II) Metallocompound and Olaparib Synergy for Cancer Combination Therapy

[Image: see text] Synergistic drug combinations can extend the use of poly(ADP-ribose) polymerase inhibitors (PARPi) such as Olaparib to BRCA-proficient tumors and overcome acquired or de novo drug resistance. To identify new synergistic combinations for PARPi, we screened a “micro-library” comprisi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yusoh, Nur Aininie, Tiley, Paul R., James, Steffan D., Harun, Siti Norain, Thomas, Jim A., Saad, Norazalina, Hii, Ling-Wei, Chia, Suet Lin, Gill, Martin R., Ahmad, Haslina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226041/
https://www.ncbi.nlm.nih.gov/pubmed/37185020
http://dx.doi.org/10.1021/acs.jmedchem.3c00322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226041/
https://www.ncbi.nlm.nih.gov/pubmed/37185020
http://dx.doi.org/10.1021/acs.jmedchem.3c00322

Ejemplares similares